News and Announcements
Proteomics Investigates Biomarkers for Mesothelioma
- Published September 08, 2016 4:53PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
6th September 2016, ASX Announcement
- PILL commences the search for protein biomarkers in the blood that could be used to diagnose mesothelioma.
- World Health Organisation estimates put the cost of treatment, compensation and settlement upwards of AU$667,00 for every sufferer.
- Mesothelioma kills 59,000 people annually.
Perth life sciences company Proteomics International Laboratories Limited (PILL, ASX: PIQ) has begun the detailed search for proteins associated with asbestos mesothelioma.
The research aim to develop a simple blood test for the disease, which could lead to early diagnosis for some of the many thousands of currently undiagnosed people who will die from mesothelioma each year.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
